Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Bristol-Myers Squibb's YERVOY® Wins Prestigious Prize for Best Biotechnology Product | IPIRA
Bristol Myers Squibb - Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
Owkin announces multi-year clinical data science strategic collaboration with Bristol Myers Squibb - Owkin
Bristol Myers Squibb - Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib) - International Psoriasis Council
JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff | Fierce Pharma
Sulayman Benmerzoug posted on LinkedIn
Bristol Myers Squibb - Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
BMS Press Release is out now - Lung Cancer Europe
Bristol Myers Squibb - Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman
Bristol Myers Squibb Donates $11 Million to Advance Health Equity | Business Wire
Bristol Myers Squibb - Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Analyzing Footnote Disclosure of Pension Buy-out In a | Chegg.com
nktr20191213ex1035
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
Bristol Myers looks to new CEO as competition from generic drugs heats up | Reuters
Bristol Myers Squibb - Bristol Myers Squibb Invests in Europe with New Cell Therapy Manufacturing Site Planned in the Netherlands
Brésil. 22nd octobre 2022. Sur cette photo, le logo Bristol Myers Squibb ( BMS) s'affiche sur l'écran d'un smartphone. (Photo de Rafael Henrique/SOPA Images/Sipa USA) crédit: SIPA USA/Alay Live News Photo Stock -
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery
Company News | Newsroom | SAMSUNG BIOLOGICS
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi®for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Bristol Myers Squibb - Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program
